📰 Marginal Zone News
Page 2 - Marginal Zone News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Marginal Zone. Real-time updates on events, politics, business and more.
September 7, 2022
NEW YORK CITY (dpa-AFX) - Cipla Limited has received final approval for its Abbreviated New Drug Application for Lenalidomide Capsule 5 mg, 10 mg, 15 mg and 25 mg from the FDA. Cipla's Lenalidomide
September 7, 2022
CIPLA RECEIVES USFDA APPROVAL FOR GENERIC VERSION OF REVLIMID® Mumbai, India/ New Jersey, United States, September 7, 2022: Cipla... | September 7, 2022
August 12, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
May 18, 2022
Global Orphan Drugs Rare Disease Therapy Market Opportunity Estimated At USD 350 Billion By 2021 Says Kuick Research
March 3, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
February 22, 2022
GuruFocus Article or News written by Business Wire and the topic is about:
February 22, 2022
BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma - read this article along with other careers information, tips and advice on BioSpace
December 11, 2021
Data from the CITADEL program of parsaclisib in patients with follicular, marginal zone and mantle cell lymphomas were accepted as oral presentations at the 63rd American Society of Hematology Annual
February 9, 2021
Share this article LAS VEGAS, Feb. 9, 2021 /PRNewswire/ -- DelveInsights " Marginal Zone Lymphoma (MZL) Market" report provides a complete comprehension of the Marginal Zone Lymphoma, historical and forecasted epidemiology and the MZL market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Marginal Zone Lymphoma market report also proffers an analysis of recent MZL treatment practice/algorithm, market drivers, market barriers and un...